<DOC>
	<DOCNO>NCT01881633</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , pharmacokinetics single dose study three ascend dose cohort ISU302 healthy subject .</brief_summary>
	<brief_title>A Study Tolerability , Safety , Pharmacokinetics ISU302 Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Gaucher Disease</mesh_term>
	<criteria>Healthy male volunteer , age ≥ 20 ≤ 45 year old Weight ≥ 50 , calculate body mass index 17 25 kg/m2 BMI = ( Weight [ kg ] ) / ( height [ ] ) 2 Subject inform investigational nature study voluntarily agree participate study comply relevant instruction write Considered ineligible screen test ( medical history , physical examination , ECG , safety laboratory test ) perform within 35 day prior study start ( dose investigational product ) With symptom indicate acute disease within 28 day prior start study ( dose investigational product ) History presence clinically significant active cardiovascular , respiratory , renal , endocrine , hematological , gastrointestinal , central nervous system , psychiatric disorder , autoimmune disease , malignant tumor Any medical history may affect drug absorption , distribution , metabolism excretion ( e.g. , inflammatory gastric disease , gastric intestinal ulcer , hepatic renal disease ) With presence clinically significant allergic disease ( include mild allergic rhinitis allergic dermatitis need medication ) With presence clinically significant hypersensitivity drug With hemolytic anemia , anemia due blood loss ( Hb &lt; 14g/dL Hct &lt; 42 % ) With result safety laboratory test 1 . AST ( Aspartate Transaminase ) ALT ( Alanine Transaminase ) &gt; 1.5 time upper normal limit 2 . Total bilirubin &gt; 1.5 time upper normal limit Subject immune deficiency medication immune suppressant Participation clinical study within 60 day prior start study ( dose investigational product ) Use drug , possibly affect drug metabolize enzyme , within 1 month prior dose , drug , possibly affect result clinical trial within 10 day use drug pass 5 x halflife drug Donated whole blood within 60 day , transfuse within 20 day study History alcohol abuse ( &gt; 14 units/week ) subject could stop drink alcohol beverage study period Heavy smoker ( &gt; 10 cigarettes/day ) subject could stop smoking study period Unwillingness inability follow procedure outline protocol Positive pregnancy test urine unwilling follow contraception study period follow 3 month ( female subject ) .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>gaucher disease , imiglucerase , ISU302</keyword>
</DOC>